Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.